Bibliography
- Drossman DA , CamilleriM, MayerEA, WhiteheadWE: AGA technical review on irritable bowel syndrome.Gastroenterology123, 2108–2131 (2002).
- Camilleri M : Management of the irritable bowel syndrome.Gastroenterology120, 652–668 (2001).
- Locke GR III, Zinsmeister AR, Talley NJ, Fett SL, Melton LJ III: Familial association in adults with functional gastrointestinal disorders. Mayo Clin. Proc.75, 907–912 (2000).
- Morris-Yates A , TalleyNJ, BoycePM, NandurkarS, AndrewsG: Evidence of a genetic contribution to functional bowel disorder.Am. J. Gastroenterol.93, 1311–1317 (1998).
- Levy RL , JonesKR, WhiteheadWE, Feld SI, Talley NJ, Corey LA: Irritable bowel syndrome in twins: hereditary and social learning both contribute to etiology. Gastroenterology121, 799–804 (2001).
- Kalantar JS , LockeGR 3rd, Zinsmeister AR, Beighley CM, Talley NJ: Familial aggregation of irritable bowel syndrome: a prospective study. Gut52, 1703–1707 (2003).
- Camilleri M : Is there a SERT-ain association with IBS? Gut 53, 1396–1399 (2004).
- Kim HJ , CamilleriM, CarlsonPJ et al.: Association of distinct α-2 adrenoceptor and serotonin transporter polymorphisms with constipation and somatic symptoms in functional gastrointestinal disorders. Gut53, 829–837 (2004).
- Holtmann G , SiffertW, HaagS et al.: G-protein β3 subunit 825 CC genotype is associated with unexplained (functional) dyspepsia. Gastroenterology126, 971–979 (2004).
- Drossman DA , CorazziariE, TalleyNJ, ThompsonWG, WhiteheadWE (Eds): The Functional Gastrointestinal Disorders: Diagnosis, Pathophysiology and Treatment: A Multinational Consensus. Degnon Associates, McLean, VA, USA (2000).
- Thompson WG , LongstrethGF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA: Functional bowel disorders and functional abdominal pain. Gut45(Suppl. 2), 43–47 (1999).
- Park M -I, Camilleri M: Genetics and genotypes in IBS: implications for diagnosis and treatment. In: Gastroenterol. Clin. North Am.: Irritable Bowel Syndrome. Talley NJ (Ed.), Elsevier Publishers, Philadelphia, PA, USA, 34(2), 305–317 (2005).
- Saito YA , LockeGR, TalleyNJ: The genetics of irritable bowel syndrome.Clin. Gastroenterol. Hepatol. (In press).
- Delgado-Aros S , CamilleriM, CremoniniF, FerberI, StephensD, BurtonDD: Contributions of gastric volumes and gastric emptying to meal size and post-meal symptoms in functional dyspepsia.Gastroenterology127, 1685–1694 (2004).
- Fischler B , VandenbergheJ, PersoonsP et al.: Evidence-based subtypes in functional dyspepsia with confirmatory factor analysis: psychosocial and physiopathological correlates. Gastroenterology120, 268–276 (2001).
- Castillo EJ , CamilleriM, LockeGR et al.: A community-based, controlled study of the epidemiology and pathophysiology of dyspepsia. Clin. Gastroenterol. Hepatol.2, 985–996 (2004).
- Barbara L , CamilleriM, CorinaldesiR et al.: Definition and investigation of dyspepsia. Consensus of an international ad hoc working party. Dig. Dis. Sci.34, 1272–1276 (1989).
- Drossman DA , LiZ, AndruzziE et al.: USA householder survey of functional gastrointestinal disorders: prevalence, sociodemography and health impact. Dig. Dis. Sci.38, 1569–1580 (1993).
- Creed F , FernandesL, GuthrieE et al.: North of England IBS Research Group: The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology124, 303–317 (2003).
- von der Ohe MR, Hanson RB, Camilleri M: Serotonergic mediation of postprandial colonic tonic and phasic responses in humans. Gut35, 536–541 (1994).
- von der Ohe MR , CamilleriM, KvolsLK: A 5-HT3 antagonist corrects the postprandial colonic hypertonic response in carcinoid diarrhea.Gastroenterology106, 1184–1189 (1994).
- Kozlowski CM , GreenA, GrundyD, BoissonadeFM, BountraC: The 5-HT3 receptor antagonist alosetron inhibits the colorectal distention induced depressor response and spinal c-fos expression in the anaesthetised rat.Gut46, 474–480 (2000).
- Delvaux M , LouvelD, MametJP, Campos-OriolaR, FrexinosJ: Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome.Aliment. Pharm. Ther.12, 849–855 (1998).
- Berman SM , ChangL, SuyenobuB et al.: Condition-specific deactivation of brain regions by 5-HT3 receptor antagonist alosetron. Gastroenterology123, 969–977 (2002).
- Cremonini F , Delgado-ArosS, CamilleriM: Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials.Neurogastroenterol. Motil.15, 79–86 (2003).
- Chey WD , CashBD: Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea.Expert Opin. Investig. Drugs14, 185–193 (2005).
- Grider JR , Foxx-OrensteinAE, JinJG: 5-hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine.Gastroenterology115, 370–380 (1998).
- Schikowski A , ThewissenM, MathisC, RossHG, EnckP: Serotonin type-4 receptors modulate the sensitivity of intramural mechanoreceptive afferents of the cat rectum.Neurogastroenterol. Motil.14, 221–227 (2002).
- Coffin B , FarmachidiJP, RueeggP, BastieA, BouhassiraD: Tegaserod, a 5-HT4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects.Aliment. Pharmacol. Ther.17, 577–585 (2003).
- Evans BW , ClarkWK, MooreDJ, Whorwell PJ: Tegaserod for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev. (1), CD003960 (2004).
- Johanson JF , WaldA, TougasG et al.: Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial. Clin. Gastroenterol. Hepatol.2, 796–805 (2004).
- Evans WE , RellingMV: Pharmacogenomics: translating functional genomics into rational therapeutics.Science286, 487–491 (1999).
- Drossman DA , TonerBB, WhiteheadWE et al.: Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology125, 19–31 (2003).
- Shulman RW , OzdemirV: Psychotropic medications and cytochrome P450 2D6: pharmacokinetic considerations in the elderly.Can. J. Psychiatr.42(Suppl. 1), 4S–9S (1997).
- Evans DAP , MahgoubA, SloanTP, IdleJR, SmithRL: A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.J. Med. Genet.17, 102–105 (1980).
- Gonzalez FJ , SkodaRC, KimuraS et al.: Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature331, 442–446 (1988).
- Relling MV , CherrieJ, SchellMJ, Petros WP, Meyer WH, Evans WE: Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects. Clin. Pharmacol. Ther.50, 308–313 (1991).
- Kalow W : The metabolism of xenobiotics in different populations.Can. J. Physiol. Pharm.60, 1–12 (1982).
- Musa MN , MiesckeKJ: Pharmacogenetics of desipramine metabolism.Int. J. Clin. Pharmacol. Ther.32, 126–130 (1994).
- Furman KD , GrimmDR, MuellerT et al.: Impact of CYP2D6 intermediate metabolizer alleles on single-dose desipramine pharmacokinetics. Pharmacogenetics14, 279–284 (2004).
- Murphy MP , BeamanME, ClarkLS et al.: Prospective CYP2D6 genotyping as an exclusion criterion for enrollment of a Phase III clinical trial. Pharmacogenetics10, 583–590 (2000).
- Caraco Y : Genes and the response to drugs.N. Engl. J. Med.351, 2867–2869 (2004).
- Lotsch J , SkarkeC, LiefholdJ, Geisslinger G: Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. Clin. Pharmacokinet.43, 983–1013 (2004).
- Gonenne J , FerberI, BurtonD et al.: Effect of a peripheral mu-opioid antagonist, alvimopan on gastrointestinal transit in health: reversal of codeine effects and stimulation of colon transit. Gastroenterology128, A94 (2005).
- Aklillu E , PerssonI, BertilssonL, Johansson I, Rodrigues F, Ingelman-Sundberg M: Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J. Pharmacol. Exp. Ther.278, 441–446 (1996).
- Dalén P , DahlML, RuizMLB, NordinJ, BertilssonL: 10-Hydroxylation of nortriptyline in white persons with 0,1, 2, 3, and 13 functional CYP2D6 genes.Clin. Pharmacol. Ther.63, 444–452 (1998).
- Kearns GL , RobinsonPK, WilsonJT et al. and the Pediatric Pharmacology Research Unit Network: Cisapride disposition in neonates and infants: in vivo reflection of cytochrome P450 3A4 ontogeny. Clin. Pharmacol. Ther.74, 312–325 (2003).
- Kaplan EL , WinstonAP, SchoenholtzJC et al.: Oral erythromycin and the risk of sudden death. N. Engl. J. Med.352, 301–304 (2005).
- Lachman HM , PapolosDF, SaitoT, YuYM, SzumlanskiCL, WeinshilboumRM: Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders.Pharmacogenetics6, 243–245 (1996).
- Cremonini F , CamilleriM, McKinzieS et al.: Effect of CCK-1 antagonist, dexloxiglumide, in female patients with irritable bowel syndrome: a pharmacodynamic and pharmacogenomic study. Am. J. Gastroenterol.100, 652–663 (2005).
- Camilleri CE , CarlsonPJ, CamilleriM et al.: A study of candidate genotypes associated with dyspepsia in a USA community. Am. J. Gastroenterol. (In press).
- Pata C , ErdalME, DericiE, YazarA, Kanik A, Ulu O: Serotonin transporter gene polymorphism in irritable bowel syndrome. Am. J. Gastroenterol.97, 1780–1784 (2002).
- Yeo A , BoydP, LumsdenS et al.: Association between a functional polymorphism in the serotonin transporter gene and diarrhea-predominant irritable bowel syndrome in women. Gut53, 1452–1458 (2004).
- Lee DY , ParkHJ, KimWH, LeeSI, SeoYJ, ChoiYC: Serotonin transporter gene polymorphism in healthy adults and patients with irritable bowel syndrome.Korean J. Gastroenterol.43, 18–22 (2004).
- Gonsalkorale WM , PerreyC, PravicaV, WhorwellPJ, HutchinsonIV: Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component? Gut 52, 91–93 (2003).
- Veek P , KroonY, BergM, VerspagetH, MascleeA: Tumor necrosis factor α and interleukin 10 gene polymorphisms in irritable bowel syndrome.Gastroenterology126, A52 (2004).
- Cami J , FarreM: Drug addiction.N. Engl. J. Med.349, 975–986 (2003).
- Camilleri M , AtanasovaE, CarlsonPJ et al.: Serotonin transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome.Gastroenterology123, 425–432 (2002).
- Holtmann G , SiffertW, GroteE et al.: G-protein mediated receptor-cell-coupling as a predictor for the long term response to treatment in patients with functional dyspepsia.Gastroenterology124, A-80 (2003).
- Ormsbee III HS, Fondacaro JD: Action of serotonin on the gastrointestinal tract. Proc. Soc. Exp. Biol. Med.178, 333–338 (1985).
- Gershon MD : Review article: roles played by 5-hydroxytryptamine in the physiology of the bowel.Aliment. Pharmacol. Ther.13, 15–30 (1999).
- Kim D -Y, Camilleri M: Serotonin: a mediator of the brain-gut connection. Am. J. Gastroenterol.95, 2698–2709 (2000).
- von der Ohe MR, Hanson RB, Camilleri M: Serotonergic mediation of postprandial colonic tonic and phasic responses in humans. Gut35, 536–541 (1994).
- Ragnarsson G , BodemarG: Pain is temporarily related to eating but not to defecation in irritable bowel syndrome (IBS). Patients’ descriptions of diarrhea, constipation and symptom variation during a prospective 6-week study.Eur. J. Gastroenterol. Hepatol.10, 415–421 (1998).
- Choi M -G, Camilleri M, O’Brien MD, Kammer PP, Hanson RB: A pilot study of motility and tone of the left colon in diarrhea due to functional disorders and dysautonomia. Am. J. Gastroenterol.92, 297–302 (1997).
- Reif A , LeschKP: Toward a molecular architecture of personality.Behavioural Brain Res.139, 1–20 (2003).
- Blakely RD , BaumanAL: Biogenic amine transporters: regulation in flux.Curr. Opin. Neurobiol.10, 328–336 (2000).
- Masson J , SagnC, HamonM, Mestikawy SE: Neurotransmitter transporters in the central nervous system. Pharmacol. Rev.51, 439–464 (1999).
- Chen J -X, Pan H, Rothman TP, Wade PR, Gershon MD: Guinea pig 5-HT transporter: cloning, expression, distribution, and function in intestinal sensory reception. Am. J. Physiol.275, G433–G438, (1998).
- Wade PR , ChenJ, JaffeB, KassemIS, BlakelyRD, GershonMD: Localization and function of a 5-HT transporter in crypt epithelia of the gastrointestinal tract.J. Neurosci.16, 2352–2364 (1996).
- Chang L , AmeenVZ, DukesGE, McSorley DJ, Carter EG, Mayer EA: A dose-ranging, Phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Am. J. Gastroenterol.100, 115–123 (2005).
- Lesch KP , BengelD, HeilsA et al.: Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region.Science274, 1527–1531 (1996).
- de Leon J , SusceMT, PanRM, FairchildM, KochWH, WedlundPJ: The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation.J. Clin. Psychiatry66(1), 15–27 (2005).